Abstract
Novel coronavirus (nCoV-19) infection has been declared a pandemic by WHO. More than 223 countries are under the attack of this emergency situation. Primarily, pneumocytes encountered by the nCoV-19 via ACE-2 receptor cause pulmonary edema, damage to alveolar cells, production of inflammatory cells, and hypoxia. It has been found that patients with co-existing cardiovascular diseases are more prone to the infection, and severe cardiovascular dysfunction was further observed when infected with nCoV-19. There is no substantial mechanism available for the pathogenesis of this cardiovascular dysfunction; therefore, we herein present a possible mechanistic approach of cardio-toxicity by nCov-19 infection. The hypothesis of this study is based on immunopathology of nCoV-19 in pneumocytes, presence of ACE-2 on cardiomyocytes membrane, cytokine storm, genomic analysis of virus in cardiac tissue, and several reports published on the cardiovascular complications in nCoV-19 across the globe. We have also analyzed the cardiotoxic profile of recently used repurposed and investigational drugs and highlighted their possible cardiotoxic consequences and drug interactions with cardiovascular medicines, such as statins and anti-coagulants.
Keywords: COVID-19, cardiac complications, cytokine storm, pneumocytes, immunopathology, inflammation, cardiac troponin T, ACE-2 receptor.
Coronaviruses
Title:Mechanism of Cardiac Pathogenesis and Cardiotoxicity of Anti- COVID-19 Drugs
Volume: 2 Issue: 9
Author(s): Ashif Iqubal, Farazul Hoda, Abul Kalam Najmi and Syed Ehtaishamul Haque*
Affiliation:
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi- 110062,India
Keywords: COVID-19, cardiac complications, cytokine storm, pneumocytes, immunopathology, inflammation, cardiac troponin T, ACE-2 receptor.
Abstract: Novel coronavirus (nCoV-19) infection has been declared a pandemic by WHO. More than 223 countries are under the attack of this emergency situation. Primarily, pneumocytes encountered by the nCoV-19 via ACE-2 receptor cause pulmonary edema, damage to alveolar cells, production of inflammatory cells, and hypoxia. It has been found that patients with co-existing cardiovascular diseases are more prone to the infection, and severe cardiovascular dysfunction was further observed when infected with nCoV-19. There is no substantial mechanism available for the pathogenesis of this cardiovascular dysfunction; therefore, we herein present a possible mechanistic approach of cardio-toxicity by nCov-19 infection. The hypothesis of this study is based on immunopathology of nCoV-19 in pneumocytes, presence of ACE-2 on cardiomyocytes membrane, cytokine storm, genomic analysis of virus in cardiac tissue, and several reports published on the cardiovascular complications in nCoV-19 across the globe. We have also analyzed the cardiotoxic profile of recently used repurposed and investigational drugs and highlighted their possible cardiotoxic consequences and drug interactions with cardiovascular medicines, such as statins and anti-coagulants.
Export Options
About this article
Cite this article as:
Iqubal Ashif , Hoda Farazul , Najmi Kalam Abul and Haque Ehtaishamul Syed *, Mechanism of Cardiac Pathogenesis and Cardiotoxicity of Anti- COVID-19 Drugs, Coronaviruses 2021; 2 (9) : e030821189346 . https://dx.doi.org/10.2174/2666796701999201222113227
DOI https://dx.doi.org/10.2174/2666796701999201222113227 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Old Drugs for New: Contemporary Immunosuppressant Development
Medicinal Chemistry Reviews - Online (Discontinued) Patent Selections
Recent Patents on Biotechnology The Impact of Probiotic on Gut Health
Current Drug Metabolism Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews Mesenchymal Stem Cells: A Potent Cell Source for COVID-19
Coronaviruses The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting Platelet-Neutrophil Interactions in Giant-Cell Arteritis
Current Pharmaceutical Design Gut Emotions - Mechanisms of Action of Probiotics as Novel Therapeutic Targets for Depression and Anxiety Disorders
CNS & Neurological Disorders - Drug Targets Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Radiotracers in Oncology
Current Radiopharmaceuticals Role of miRNAs in Coronary Artery Disease
Current Signal Transduction Therapy Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Current Pharmaceutical Design Role of Cytokines in Regulating Feeding Behaviour
Current Drug Targets Pharmacological and Clinical Applications of Natriuretic Peptides: Accepted Knowledges or Changing Views?
Current Pharmaceutical Analysis AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Schizophrenia: Causes and Treatments
Current Pharmaceutical Design Omega-3 and Renal Function in Older Adults
Current Pharmaceutical Design Current Pharmacological Treatment of Nonalcoholic Fatty Liver
Current Medicinal Chemistry Synthesis and Anti-tubercular Activity of 6-(<i>4</i>-Chloro/Methyl-phenyl)-4- Arylidene-4,5-dihydropyridazin-3(2<i>H</i>)-one Derivatives Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Therapeutic Hypothermia for Cardiopulmonary Resuscitation: Why, When and How
Current Cardiology Reviews